Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Primary Purpose
Bone Marrow Transplantation, Respiratory Insufficiency
Status
Unknown status
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
hemofiltration
Sponsored by
About this trial
This is an interventional treatment trial for Bone Marrow Transplantation focused on measuring Hemofiltration, Pediatrics
Eligibility Criteria
Inclusion Criteria: hematopoietic stem cell recipient respiratory failure fulfilling ARDS criteria mechanical ventilation (invasive / non-invasive) Exclusion Criteria: extracorporeal membrane oxygenation (ECMO) predominance of congestive heart failure code status: a patient must be willing to accept invasive mechanical ventilation if clinically indicated
Sites / Locations
- Children's Hospital and Research Center
- Children's Healthcare of Atlanta @ EglestonRecruiting
- Duke UniversityRecruiting
- Children's Hospital of Philadelphia
- Children's Hospital of British Columbia
- University of UlmRecruiting
- Great Ormond Street HospitalRecruiting
Outcomes
Primary Outcome Measures
Survival
Secondary Outcome Measures
PELOD organ failure score
number of ventilator-free days
duration of hospitalization
functional outcome score
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00120575
Brief Title
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
Official Title
Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation
Study Type
Interventional
2. Study Status
Record Verification Date
December 2006
Overall Recruitment Status
Unknown status
Study Start Date
January 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2008 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Stanford University
4. Oversight
5. Study Description
Brief Summary
For children undergoing bone marrow transplantation, respiratory failure is a devastating complication, with mortality expectations well above 60%. The researchers have devised a novel strategy that may greatly improve survival. Hemofiltration, a continuous form of dialysis, was designed as a therapy for critically ill patients with kidney failure. A semi-permeable membrane removes plasma water and solutes (up to about 35,000 Daltons molecular weight). The researchers have treated immuno-compromised children with respiratory failure with hemofiltration. Many inflammatory molecules are of a size well below the limit of the filter. Hemofiltration might remove a critical amount of this inflammatory material, attenuating the unregulated inflammatory response that is central to the development of respiratory failure and progression to multiple organ failure and death. The researchers are conducting a multi-center trial of early continuous hemofiltration for respiratory failure in children following bone marrow transplantation. The researchers will analyze blood and ultrafiltrate using sensitive proteomic methods to detect several inflammatory biochemicals known to be active in this disease, looking for evidence that early active hemofiltration alters the inflammatory response. The researchers will test whether 'early' hemofiltration produces greater survival from respiratory failure in this vulnerable population.
Detailed Description
For children undergoing bone marrow transplantation, respiratory failure carries mortality expectations well above 60%. The researchers have published preliminary evidence that continuous hemofiltration may greatly improve survival, if filtration is begun when the child first fulfills clinical criteria for ARDS. This is a departure from standard practice, as hemofiltration is usually begun later in the course (if at all) when multiple organ failure is entrenched. Hemofiltration, a 'renal replacement therapy' for critically ill patients, is a slow, continuous process in which a semi-permeable membrane removes plasma water and solutes (up to about 35 kiloDaltons). Many cytokine and chemokine molecules are smaller than the molecular weight limit of the filter; hemofiltration might remove a critical amount, attenuating the unregulated inflammatory response responsible for respiratory failure and progression to multiple organ failure and death. The researchers will conduct a multi-center randomized trial assessing the effect of hemofiltration on survival from respiratory after bone marrow (or more precisely, hematopoietic stem cell) transplantation. The researchers will perform sensitive proteomic assays of serum and ultrafiltrate, to detect the presence of cytokines and chemokines known to be active in idiopathic pneumonia syndrome. Resulting profiles will constitute a uniquely complex description of ultrafiltrate and may provide evidence for modulation of immune function by hemofiltration.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bone Marrow Transplantation, Respiratory Insufficiency
Keywords
Hemofiltration, Pediatrics
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
112 (false)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
hemofiltration
Primary Outcome Measure Information:
Title
Survival
Secondary Outcome Measure Information:
Title
PELOD organ failure score
Title
number of ventilator-free days
Title
duration of hospitalization
Title
functional outcome score
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
hematopoietic stem cell recipient
respiratory failure fulfilling ARDS criteria
mechanical ventilation (invasive / non-invasive)
Exclusion Criteria:
extracorporeal membrane oxygenation (ECMO)
predominance of congestive heart failure
code status: a patient must be willing to accept invasive mechanical ventilation if clinically indicated
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Joseph V DiCarlo, MD
Phone
(650) 497-8850
Email
jdicarlo@stanford.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph V DiCarlo, MD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital and Research Center
City
Oakland
State/Province
California
ZIP/Postal Code
94609
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vivienne Newman, MD
First Name & Middle Initial & Last Name & Degree
Vivienne Newman, MD
Facility Name
Children's Healthcare of Atlanta @ Egleston
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Fortenberry, MD
First Name & Middle Initial & Last Name & Degree
James Fortenberry, MD
Facility Name
Duke University
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ira Cheifetz, MD
First Name & Middle Initial & Last Name & Degree
Ira Cheifetz, MD
Facility Name
Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vinay Nadkarni, MD
First Name & Middle Initial & Last Name & Degree
Vinay Nadkarni, MD
Facility Name
Children's Hospital of British Columbia
City
Vancouver
State/Province
British Columbia
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Skippen, MD
First Name & Middle Initial & Last Name & Degree
Gordon Krahn
First Name & Middle Initial & Last Name & Degree
Peter Skippen, MD
Facility Name
University of Ulm
City
Ulm
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helmut Hummler, MD
First Name & Middle Initial & Last Name & Degree
Helmut Hummler, MD
Facility Name
Great Ormond Street Hospital
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Quen Mok, MB BS
First Name & Middle Initial & Last Name & Degree
Quen Mok, MB BS
12. IPD Sharing Statement
Citations:
PubMed Identifier
14528104
Citation
DiCarlo JV, Alexander SR, Agarwal R, Schiffman JD. Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy. J Pediatr Hematol Oncol. 2003 Oct;25(10):801-5. doi: 10.1097/00043426-200310000-00012.
Results Reference
background
PubMed Identifier
16211527
Citation
Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs. 2005 Aug;28(8):777-86. doi: 10.1177/039139880502800803.
Results Reference
background
Learn more about this trial
Hemofiltration for Respiratory Failure After Bone Marrow Transplantation
We'll reach out to this number within 24 hrs